Physician profile
Amanda Simonton
NPI 1134606833
$7,604.54
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,116 · 2022: $5,488.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $4,429.54 | 2022 | |
| Alkermes, INC. | $2,231.42 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $265.82 | 2021-2022 | |
| Abbvie INC. | $260.74 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $162.45 | 2022 | |
| Sunovion Pharmaceuticals INC. | $107.46 | 2022 | |
| Biogen, INC. | $104.73 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.18 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.20 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Simonton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.